NCT07001618
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07001618
Title Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer (IMMUNOLIFE2)
Acronym IMMUNOLIFE2
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Gustave Roussy, Cancer Campus, Grand Paris
Indications
Therapies
Age Groups: senior | adult
Covered Countries FRA

Facility Status City State Zip Country Details
Centre Georges François Leclerc NOT_YET_RECRUITING Dijon 21079 France Details
CHU Grenoble NOT_YET_RECRUITING Grenoble 38043 France Details
Hôpital Bichat - Claude Bernard NOT_YET_RECRUITING Paris 75018 France Details
Hôpital Foch RECRUITING Suresnes 92150 France Details
Centre Hospitalier Sainte Musse Toulon RECRUITING Toulon 83000 France Details
Gustave Roussy RECRUITING Villejuif 94800 France Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field